source
- Vaderis raises $152 million Series B to launch Phase 3 trial for rare vascular diseaseVaderis Therapeutics announced it has closed an oversubscribed $152 million Series B round to fund its AKT inhibitor program. The capital will support a newly launched Phase 3 study of the oral dr…
- Sanofi faces shortage of two Pompe disease drugs after FDA flags manufacturing issuesSanofi has reported a shortage of two medicines used to treat Pompe disease. The shortage emerged after the U.S. Food and Drug Administration issued a warning about manufacturing problems at the co…